Remove 2006 Remove Leads Remove Sales
article thumbnail

Market outlook to 2032: future trends across the seven major markets

European Pharmaceutical Review

In its report on the insomnia market published last month, GlobalData expected that sales for DORAs, which offer a new mechanism of action for the condition, will continue to grow at a CAGR of 8.6 billion by 2023, driven by the launch of Merck’s Belsomra and Eisai’s lemborexant (E-2006). million in sales by 2032.

article thumbnail

The Fastest Growing Companies in Boston Hiring For Sales

CloserIQ

Boston is emerging as one of the hottest startup cities in the country, which is great news for sales professionals. These companies are all backed by venture capital and are currently hiring in sales roles. This is by no means an exhaustive list, but here are some great companies to consider for your next sales job. ProfitWell.

Sales 76
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Chiesi expands rare disease portfolio with Amryt Pharma acquisition

pharmaphorum

Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 Additionally, its top-selling drug, Myalept or Myalepta, had third-quarter sales of $37.9m. in an all-cash transaction at $14.50

Pharma 85
article thumbnail

Will A.I. Replace the Medical Sales Workforce and Surgeons? With Edouard Saget

Evolve Your Success

In the changing balance between innovation and tradition, medical sales succeeds with personal connection, persistence, and the commitment to link technology and patient care. For today’s episode, we have Edouard Saget to discuss the big question: Will AI replace medical sales workforce and surgeons? Tune in to find out!

article thumbnail

Bayer plans to scale back women’s health R&D

Pharmaceutical Technology

Following Bayer’s takeover of Schering Healthcare in 2006, where it inherited the oral contraceptive Yasmin (ethinyl estradiol + drospirenone) and the intrauterine device Mirena (levonorgestrel-releasing system), the German drugmaker has become one of the world’s leading pharmaceutical specialists in women’s health.

article thumbnail

Making an Impact During Disease Awareness Days, Weeks, and Months

PM360

In 2006, Facebook boomed in mainstream popularity and MySpace was one of the most visited websites. In a world that is so driven by metrics, data, and ROI, it’s easy to write off awareness campaigns as unsuccessful or unimpactful if they aren’t driving sales or directly leading to better outcomes.

Media 92
article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

Meulenbelt highlighted “the desire to have broader launches is very good,” since under the current model, if OMP companies can make a major part of their sales in a limited number of markets they are unlikely to launch elsewhere, limiting patient access. THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2006.